Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-08-21

Intellia Therapeutics, Inc.

Intellia develops CRISPR-based gene editing medicines for severe diseases, led by hereditary angioedema and transthyretin amyloidosis programs.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From binary CRISPR story to franchise test

The five-year case depends less on blue-sky gene-editing hype than on one hard conversion: turn strong HAE data into approval, reimbursement and treatment-center throughput. If that happens, a focused commercial franchise plus partial platform reuse can justify multi-bagger upside.

Analysis

Thesis

Intellia’s five-year upside is a company-shape change: lonvo-z can turn CRISPR from collaboration revenue into a real rare-disease franchise, while nex-z recovery and selective licensing add repeatability without needing a heroic full-platform blue-sky outcome.

Last Economy Alignment

AI helps Intellia move faster in discovery, trial operations and regulatory prep, but value still comes from hard biological IP, patient data rights, manufacturing know-how and trusted treatment workflows.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.6x (from 5 most recent analyses)

Reasoning

If lonvo-z launches well, Intellia stops looking like a cash-burning science option and starts looking like a focused rare-disease company with a reusable editing engine. The upside does not require owning all of CRISPR; it requires one real franchise, a still-viable second franchise and enough discipline to avoid excessive dilution before cash conversion improves.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The upside is real, but the path is sequential and fragile: filing completeness, FDA acceptance, approval, payer design and treatment-center throughput must all line up before lonvo-z is valued like a franchise. If nex-z fails to regain credibility, Intellia could still win approval yet miss the broader platform rerating that makes the 2031 case more compelling.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company-specific disclosure changed the thesis in the last 7-10 days after the August 6 business update and August 7 inducement-grant filing.
The market is now focused less on lonvo-z efficacy and more on filing completeness, FDA acceptance timing and launch readiness.
Near-term repricing has shifted toward September conference commentary ahead of the expected 2H26 BLA acceptance window.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.35

They control hard-to-copy gene-editing data, know-how and a potential one-time treatment workflow, so AI mostly helps them move faster rather than replacing them. The constraint is trust: regulators, safety follow-up and payer approval still decide how much value they can capture.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$23.94

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research